Novo Nordisk AS (NOVO B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH7427D
- Pages: 117
- November 2018
- Total Views:1150
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company's product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Novo Nordisk AS (NOVO B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Venture Financing 18
Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18
Partnerships 20
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Licensing Agreements 34
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Equity Offering 57
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Asset Transactions 60
Novo Nordisk Plans to Sell Inflammation Business 60
Acquisition 61
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS-Key Competitors 63
Novo Nordisk AS-Key Employees 64
Novo Nordisk AS-Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 70
Strategy And Business Planning 70
Nov 01, 2018: Novo Nordisk to buy rights to Strongbridge's Macrilen for USD 145m 70
Oct 01, 2018: Novo Nordisk to establish California manufacturing site for stem cell-based therapies 71
Sep 12, 2018: Novo Nordisk research centre opens in Oxford 12 Sep 2018 72
May 16, 2018: Novo Nordisk increases commitment to stem cell-based therapies 74
Feb 12, 2018: Novo Nordisk Plans USD 65M Expansion of Clayton Manufacturing Site 75
Financial Announcements 76
Nov 01, 2018: Novo Nordisk''s operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018 76
May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 77
Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 78
Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 79
Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 80
May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 81
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 82
Corporate Communications 83
Oct 15, 2018: Novo Nordisk names Ludovic Helfgott executive vice president Biopharm 83
Sep 20, 2018: Novo Nordisk to lay off 400 employees in Denmark and China 84
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 85
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 86
Legal and Regulatory 87
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 87
Government and Public Interest 88
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 88
May 01, 2018: Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 90
Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 91
Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 92
Apr 17, 2017: Novo Nordisk Foundation Grant 93
Product News 94
12/15/2017: Ozempic (semaglutide) recommended for approval by the European regulatory authorities 94
Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 95
12/05/2017: Ozempic (semaglutide) approved in the US 96
10/18/2017: Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide 97
09/12/2017: More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 98
08/28/2018: Novo Nordisk reports positive results from SUSTAIN 6 trial 99
03/23/2018: Ozempic approved in Japan for the treatment of type 2 diabetes 100
03/20/2018: New diabetes drug may help people with obesity lose weight 101
03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes 102
02/09/2018: Novo Nordisk: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes 103
02/05/2018: Novo Nordisk Launches Ozempic Expanding Treatment Options for Adults with Diabetes 104
Product Approvals 105
Oct 16, 2017: Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide 105
Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 106
Clinical Trials 108
Jun 23, 2018: Ozempic Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis 108
Feb 01, 2018: Semaglutide demonstrated significant reductions in blood sugar and weight compared with dulaglutide; results published in The Lancet Diabetes & Endocrinology 109
Jan 09, 2018: Ozempic approved in Canada for the treatment of adults with type 2 diabetes 110
Aug 16, 2017: Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 112
Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 113
Other Significant Developments 114
Nov 02, 2018: Novo Nordisk to lay off 1,300 employees 114
Aug 08, 2018: Novo Nordisk's operating profit decreased by 8% in danish kroner and increased by 4% in local currencies in the first six months of 2018 115
Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 116
Appendix 117
Methodology 117
About GlobalData 117
Contact Us 117
Disclaimer 117
List Of Figure
List of Figures
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
List Of Table
List of Tables
Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Novo Nordisk Plans to Sell Inflammation Business 60
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS, Key Competitors 63
Novo Nordisk AS, Key Employees 64
Novo Nordisk AS, Subsidiaries 65
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Novo Nordisk AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company's product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products, hormone replacement therapy and other serious chronic diseases. With subsidiaries in Europe, North America, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Novo Nordisk AS (NOVO B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Venture Financing 18
Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18
Partnerships 20
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Licensing Agreements 34
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Equity Offering 57
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Asset Transactions 60
Novo Nordisk Plans to Sell Inflammation Business 60
Acquisition 61
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS-Key Competitors 63
Novo Nordisk AS-Key Employees 64
Novo Nordisk AS-Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 70
Strategy And Business Planning 70
Nov 01, 2018: Novo Nordisk to buy rights to Strongbridge's Macrilen for USD 145m 70
Oct 01, 2018: Novo Nordisk to establish California manufacturing site for stem cell-based therapies 71
Sep 12, 2018: Novo Nordisk research centre opens in Oxford 12 Sep 2018 72
May 16, 2018: Novo Nordisk increases commitment to stem cell-based therapies 74
Feb 12, 2018: Novo Nordisk Plans USD 65M Expansion of Clayton Manufacturing Site 75
Financial Announcements 76
Nov 01, 2018: Novo Nordisk''s operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018 76
May 02, 2018: Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018 77
Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies) 78
Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 79
Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 80
May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 81
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 82
Corporate Communications 83
Oct 15, 2018: Novo Nordisk names Ludovic Helfgott executive vice president Biopharm 83
Sep 20, 2018: Novo Nordisk to lay off 400 employees in Denmark and China 84
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 85
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 86
Legal and Regulatory 87
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 87
Government and Public Interest 88
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 88
May 01, 2018: Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 90
Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 91
Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 92
Apr 17, 2017: Novo Nordisk Foundation Grant 93
Product News 94
12/15/2017: Ozempic (semaglutide) recommended for approval by the European regulatory authorities 94
Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 95
12/05/2017: Ozempic (semaglutide) approved in the US 96
10/18/2017: Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide 97
09/12/2017: More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 98
08/28/2018: Novo Nordisk reports positive results from SUSTAIN 6 trial 99
03/23/2018: Ozempic approved in Japan for the treatment of type 2 diabetes 100
03/20/2018: New diabetes drug may help people with obesity lose weight 101
03/05/2018: OZEMPIC now available for Canadians with type 2 diabetes 102
02/09/2018: Novo Nordisk: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes 103
02/05/2018: Novo Nordisk Launches Ozempic Expanding Treatment Options for Adults with Diabetes 104
Product Approvals 105
Oct 16, 2017: Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide 105
Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 106
Clinical Trials 108
Jun 23, 2018: Ozempic Provided Greater Weight Reductions for Adults With a Baseline BMI =25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis 108
Feb 01, 2018: Semaglutide demonstrated significant reductions in blood sugar and weight compared with dulaglutide; results published in The Lancet Diabetes & Endocrinology 109
Jan 09, 2018: Ozempic approved in Canada for the treatment of adults with type 2 diabetes 110
Aug 16, 2017: Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 112
Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 113
Other Significant Developments 114
Nov 02, 2018: Novo Nordisk to lay off 1,300 employees 114
Aug 08, 2018: Novo Nordisk's operating profit decreased by 8% in danish kroner and increased by 4% in local currencies in the first six months of 2018 115
Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 116
Appendix 117
Methodology 117
About GlobalData 117
Contact Us 117
Disclaimer 117
List Of Figure
List of Figures
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
List Of Table
List of Tables
Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Novo Nordisk AS, Deals By Therapy Area, 2012 to YTD 2018 11
Novo Nordisk AS, Medical Devices Deals, 2012 to YTD 2018 12
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Novo Nordisk to Acquire MACRILEN from Strongbridge Biopharma 16
Affimed Therapeutics Raises USD 20.2 Million In Series D Financing 18
Embark Biotech and Novo Nordisk Enter into Collaboration Agreement 20
Ossianix and Novo Nordisk Enter into Research and Option Agreement 21
Evotec Enters into Co-Development Agreement with Novo Nordisk 22
Kallyope and Novo Nordisk Enter into Research Agreement 23
BioLamina and Novo Nordisk Enter into Partnership 24
Prime Therapeutics Enters into Contract with Novo Nordisk 25
Metacrine Enters into Agreement with Novo Nordisk 26
Novo Nordisk Enters into Research Agreement with University of Oxford 27
Novo Nordisk Enters into Research Agreement with UW Medicine 28
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 29
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 30
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 31
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 32
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 33
Asterias Biotherapeutics Enters into Option Agreement with Novo Nordisk 34
Novo Nordisk Enters into Licensing Agreement with Epigen Biosciences 35
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 36
Novo Nordisk Enters into Research and Licensing Agreement with DUKE National University Singapore Medical School 37
Novo Nordisk Enters into Licensing Agreement with University of California San Francisco 38
Novo Nordisk Enters into Licensing Agreement with EpiDestiny 39
Novo Nordisk Enters Licensing Agreement into with reMYND 40
Kiniksa Pharma Enters into Licensing Agreement with Novo Nordisk 41
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 42
Novo Nordisk Enters into Licensing Agreement with Ablynx 43
Novo Nordisk Enters into Licensing Agreement with Emisphere 44
Novo Nordisk Expands Licensing Agreement with Genmab 45
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 46
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 47
Novo Nordisk Amends Licensing Agreement with Emisphere 48
Adimab Enters Into Licensing Agreement With Novo Nordisk 49
Pharmacyclics Amends Licensing Agreement With Novo Nordisk For PCI-27483 50
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 51
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 52
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 53
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 55
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 56
Strongbridge Biopharma to Raise USD36.69 Million in Private Placement of Shares 57
NNIT Prices IPO for USD191 Million 58
Novo Nordisk Plans to Sell Inflammation Business 60
Novo Nordisk May Acquire Global Blood Therapeutics 61
Novo Nordisk to Acquire Calibrium and MB2 62
Novo Nordisk AS, Key Competitors 63
Novo Nordisk AS, Key Employees 64
Novo Nordisk AS, Subsidiaries 65
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Novo Nordisk AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020